UNITED ~~STATESSECURITIES~~STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT ~~REPORTPursuant~~REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~May~~August 108, ~~2011Date~~2011 Date of Report (Date of ~~earliest~~ earliest event reported)

CALECO PHARMA CORP.
(Exact name of registrant as specified in its charter)

NEVADA	000-51261	20-1147435
(State or other jurisdiction of	(Commission File Number)	(IRS Employer Identification No.)
incorporation)

59 East Mall Road
Building 4, Suite 201
Long Valley, NJ	07853
(Address of principal executive offices)	(Zip Code)

(908) 752-~~4240Registrant~~4240 Registrant's telephone number, including area code

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~____~~[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

~~____~~[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

~~____~~ [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

~~____~~ [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

~~SECTION~~ITEM 15.02 –DEPARTURE ~~REGISTRANT’S~~OF ~~BUSINESS~~DIRECTORS AND ~~OPERATIONS~~CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

~~ITEM~~Effective 1August 8, 2011, Mr.01 ~~ENTRY~~F. ~~INTO~~Javier ABenedi ~~MATERIAL~~Garcia ~~DEFINITIVE~~resigned as ~~AGREEMENT~~a Director of Caleco Pharma Corp. (the “Company”) for personal reasons. There were no disagreements between Mr. Garcia and the Company regarding any matter relating to the Company’s operations, policies or practices.

~~Investor~~The ~~Relations~~Company ~~Consulting~~has ~~Agreement~~not appointed a replacement director to fill the vacancy created by Mr. Garcia’s resignation at this time.

OnSIGNATURE May 10, 2011, Caleco Pharma Corp. (the “Company”) entered into an investor relations consulting agreement (the “Agreement”) with Institutional Analysts Inc. (“IA”) whereby IA will provide investor relations consulting services to the Company. IA will provide services including, but not limited to, ongoing research and reports, newsletter distribution, introductions to brokers and counseling on the style and content of investor relations materials. The Agreement is for a one year term ending May 9, 2012. As compensation for IA’s services, the Company has agreed to:

~~(a)~~Pursuant ~~pay~~to ~~$10~~the requirements of the Securities Exchange Act of 1934,~~000~~ the registrant has duly caused this report to IAbe assigned ~~follows:~~on its behalf by the undersigned hereunto duly authorized.

(i) $2,500 on execution of the Agreement; (ii) $2,500 on or before September 10, 2011; (iii) $2,500 on or before February 10, 2012; and (iv) $2,500 on or before May 10, 2012; and

		CALECO PHARMA CORP.
Date: August 11, 2011
	By:	/s/ John Boschert
		JOHN BOSCHERT
		Chief Executive Officer, President,
		Secretary & Treasurer

~~(b) issue~~ 2~~,000,000 shares of the Company’s common stock to IA on execution of the Agreement.~~

The issuance of shares was completed pursuant to the provisions of Rule 506 of Regulation D of the Securities Act of 1933, as amended. IA represented that was an accredited investor as defined under Regulation D.

The above summary is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Exhibit Number		Description of Exhibit
10.1		Investor Relations Consulting Agreement between the Company and Institutional Analyst, Inc. dated May 10, 2011

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		CALECO PHARMA CORP.
Date: May 16, 2011
	By:	/s/ John Boschert
		JOHN BOSCHERT
		Chief Executive Officer, President,
		Secretary & Treasurer

Filing Compare · CALECO PHARMA CORP.